UCB is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders . Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext (symbol: UCB). Worldwide headquarters is located in Brussels , Belgium ; U.S. headquarters is located in Atlanta , Georgia . For more information about UCB, visit www.ucb.com